Kavita Raniga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kavita Raniga has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Aishah Nasir
The Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, UK
1 shared publicationAmy Pointon
Safety Sciences, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, UK
1 shared publication- Andrew J. Brown
GlaxoSmithKline
1 shared publication - Anthony Bahinski
Vivodyne
1 shared publication C Denning
Biodiscovery Institute, University of Nottingham, Nottingham, UK
1 shared publication- Chris Denning
Translational Medical Sciences, Biodiscovery Institute, University Park, University of Nottingham, Nottingham, NG7 2RD, UK.
1 shared publication
Latest Publications
- Open Access
- 15 February 2024
- Published by Elsevier in Cell Stem Cell
- Vol. 31 (3) , 292-311
Strengthening cardiac therapy pipelines using human pluripotent stem cell-derived cardiomyocytes
- 15 February 2024
- Published by Elsevier in Cell Stem Cell
- Vol. 31 (3) , 292-311
Open AccessStrengthening cardiac therapy pipelines using human pluripotent stem cell-derived cardiomyocytes
- Open Access
- 29 December 2023
- Published by SAGE Publications in Perspectives in Public Health
- Vol. 144 (1) , 5-8
‘Project period’: a workplace health promotion innovation in a higher education setting
- 29 December 2023
- Published by SAGE Publications in Perspectives in Public Health
- Vol. 144 (1) , 5-8
Open Access‘Project period’: a workplace health promotion innovation in a higher education setting
- 18 July 2023
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 195 (1) , 61-70
CardioMotion: identification of functional and structural cardiotoxic liabilities in small molecules through brightfield kinetic imaging
Cardiovascular toxicity is an important cause of drug failures in the later stages of drug development, early clinical safety assessment and even post-market withdrawals. Early-stage in vitro assessment of potential cardiovascular liabilities in the pharmaceutical industry involves assessment of interactions with cardiac ion channels, as well as induced pluripotent stem cell derived cardiomyocyte based functional assays, such as calcium flux and, multi-electrode-array assays. These methods are appropriate for the identification of acute functional cardiotoxicity but structural cardiotoxicity, which manifests effects after chronic exposure, is often only captured in vivo. CardioMotion is a novel, label-free, high throughput, in vitro assay and analysis pipeline which records and assesses the spontaneous beating of cardiomyocytes and identifies compounds which impact beating. This is achieved through the acquisition of brightfield images at a high framerate, combined with an optical flow-based python analysis pipeline which transforms the images into waveform data which are then parameterized. Validation of this assay with a large dataset showed that cardioactive compounds with diverse known direct functional and structural mechanisms-of-action on cardiomyocytes are identified (sensitivity = 72.9%), importantly, known structural cardiotoxins also disrupt cardiomyocyte beating (sensitivity = 86%) in this method. Furthermore, the CardioMotion method presents a high specificity of 82.5%. Impact Statement: CardioMotion enables the high throughput identification of small molecule compounds with potential cardiac liabilities, including structural cardiovascular toxicants, with high sensitivity and specificity based solely on the effect of compounds on the spontaneous beating of iPSc derived cardiomyocytes.
- 18 July 2023
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 195 (1) , 61-70
CardioMotion: identification of functional and structural cardiotoxic liabilities in small molecules through brightfield kinetic imaging
Cardiovascular toxicity is an important cause of drug failures in the later stages of drug development, early clinical safety assessment and even post-market withdrawals. Early-stage in vitro assessment of potential cardiovascular liabilities in the pharmaceutical industry involves assessment of interactions with cardiac ion channels, as well as induced pluripotent stem cell derived cardiomyocyte based functional assays, such as calcium flux and, multi-electrode-array assays. These methods are appropriate for the identification of acute functional cardiotoxicity but structural cardiotoxicity, which manifests effects after chronic exposure, is often only captured in vivo. CardioMotion is a novel, label-free, high throughput, in vitro assay and analysis pipeline which records and assesses the spontaneous beating of cardiomyocytes and identifies compounds which impact beating. This is achieved through the acquisition of brightfield images at a high framerate, combined with an optical flow-based python analysis pipeline which transforms the images into waveform data which are then parameterized. Validation of this assay with a large dataset showed that cardioactive compounds with diverse known direct functional and structural mechanisms-of-action on cardiomyocytes are identified (sensitivity = 72.9%), importantly, known structural cardiotoxins also disrupt cardiomyocyte beating (sensitivity = 86%) in this method. Furthermore, the CardioMotion method presents a high specificity of 82.5%. Impact Statement: CardioMotion enables the high throughput identification of small molecule compounds with potential cardiac liabilities, including structural cardiovascular toxicants, with high sensitivity and specificity based solely on the effect of compounds on the spontaneous beating of iPSc derived cardiomyocytes.